eli lilly tirzepatide patent expiry Republican Administration Maintains Exclusivity Stance in GLP-1 (Tirzepatide) Compounding Dispute Top drug patent expirations in

Patients experiencing unexpected side effects from a compounded product should report through MedWatch and notify their prescriber [11]

Claims data might show that a patient filled a 90-day prescription of Wegovy, then stopped

Novos obesity blockbuster semaglutide before label extension In both, liver fibrosis and resolution of MASH, Novo Nordisk's GLP1 modulator semaglutide has shown convincing results in the Phase III ESSENCE study suggesting a label extension of the obesity blockbuster

"But if compounding looks to be competition, drug makers are going to use every weapon at their disposal to push back." Compounding pharmacies, he insists, don't want to be competition and "are trying to alert patients to the fact that, if they've been taking a compounded copy of a [GLP-1] drug, that era is coming to an end." It's a hard reality for patients to accept

Document the specific reason for discontinuation (adverse reaction, contraindication, or inadequate glycemic control with specific A1C values)